Keywords: cv, thera, initiates, ph, iii, cvt-3146, california

CV Thera initiates Ph III of CVT-3146

Article | 03 November 2003

Print This

California, USA-based CV Therapeutics says that it has initiated apivotal Phase III clinical trial of CVT-3146, a selective A2A-adenosine ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in